Different batches [Regulatives / Guidelines]

posted by wienui  – Germany, Oman, 2020-03-08 10:19 (204 d 05:29 ago) – Posting: # 21225
Views: 2,420

Hi Marcelo,

» I agree with you. It was just a suggestion based on our previous experience in Brazil :-|. Sometimes we need to explain the inexplicable to health authority to avoid delays in the dossier review :-D

The use of a different batch in the fed study as asked above from taiyab.jameel could be better as you can prove batches therpeutic equivalence consistency via in vivo studies.

On the contrary, in the case of additional strength biowaiver, it is a must to use the same biobatch for which the therpeutic equivalence was proven before via in vivo BE study.

Best regards,


Complete thread:

 Admin contact
21,082 posts in 4,397 threads, 1,468 registered users;
online 3 (1 registered, 2 guests [including 2 identified bots]).
Forum time: Monday 16:49 CEST (Europe/Vienna)

A central lesson of science is that to understand complex issues
(or even simple ones), we must try to free our minds of dogma and
to guarantee the freedom to publish, to contradict, and to experiment.
Arguments from authority are unacceptable.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz